Loading company…
Shaperon develops inflammasome inhibitors and Nanobody therapeutics for inflammatory disorders.
Founded in 2008 and based in Seoul, South Korea, Shaperon develops therapies for immune-mediated inflammatory disorders, including inflammasome inhibitors and Nanobody therapeutics. Its products include NuGel®, NuSepin®, Oral HY209, Saviximab® and Papiliximab®. On June 12, 2024, it raised KRW 12.7 billion in an IPO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in